Results overview: Found 5 records in 0.02 seconds.
Articles, 5 records found
Articles 5 records found  
1.
17 p, 2.4 MB Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients / Ruiz de Porras, V. (Institut Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Cabrero de las Heras, Sara (Institut Germans Trias i Pujol) ; Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge) ; Alonso, M.H. (Universitat de Barcelona. Departament de Ciències Clíniques) ; Nieto Raya, Rocío. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques) ; Queralt, C. (Institut Germans Trias i Pujol) ; Manzano Mozo, José Luís (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Bugés, Cristina (Institut Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. [...]
2019 - 10.3390/cancers11101540
Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540  
2.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General de Alicante) ; Grávalos, Cristina (Hospital 12 de Octubre (Madrid)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica) ; Safont, María José (Hospital General de València) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital San Carlos) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Marqués de Valdecilla) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Hospital Universitario da Coruña) ; González, Encarnación (Hospital Virgen de las Nieves) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202  
3.
11 p, 912.9 KB Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis / Capdevila, Jaume (Hospital Universitari Vall d'Hebron) ; Sevilla, Isabel (Hospital Universitario Virgen de la Victoria) ; Alonso, Vicente (Medical Oncology Department, Hospital Universitario Miguel Servet) ; Antón Aparicio, Luís (Complejo Hospitalario Universitario A Coruña) ; Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Reina, Juan José (Hospital Universitario Virgen de la Macarena) ; Manzano, José Luís (Hospital Universitari Vall d'Hebron) ; Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca) ; Barriuso, Jorge (Hospital Universitario La Paz) ; Castellano, Daniel (Hospital Universitario 12 de Octubre) ; Medina, Javier (Complejo Hospitalario de Toledo) ; López, Carlos (Hospital Universitario Marqués de Valdecilla) ; Segura, Ángel (Hospital Universitario La Fe University Hospital) ; Carrera, Sergio (Hospital Universitario de Cruces) ; Crespo, Guillermo (Hospital Universitario de Burgos) ; Fuster, José (Hospital Universitario Son Dureta) ; Munarriz, Javier (Hospital Provincial de Castellón) ; García Alfonso, Pilar (Hospital Gregorio Marañón (Madrid)) ; Universitat Autònoma de Barcelona
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). [...]
2015 - 10.1186/s12885-015-1512-6
BMC Cancer, Vol. 15 (july 2015)  
4.
17 p, 2.9 MB Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway / Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Pluvinet, Raquel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Sumoy, Lauro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Howells, Lynne (University of Leicester. Departament of Cancer Studies) ; James, Mark I. (University of Leicester. Departament of Cancer Studies) ; Iwuji, Chinenye (University of Leicester. Departament of Cancer Studies) ; Manzano, José Luis (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Bugés, Cristina (Institut Germans Trias i Pujol) ; Abad, Albert (Hospital Cima Sanitas (Barcelona)) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling pathway has been proposed as an important mechanism involved in this phenomenon. [...]
2016 - 10.1038/srep24675
Scientific reports (Nature Publishing Group), Vol. 6 (April 2016)  
5.
20 p, 10.3 MB PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines / Ginés Molina, Alba (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol) ; Guardia, Cristina (Institut Germans Trias i Pujol) ; Musulén Palet, Eva (Institut Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol) ; Manzano, José Luis (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Abad, Albert (Institut Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. [...]
2015 - 10.1371/journal.pone.0123830
PloS one, Vol. 10, No. 5 (May 2015) , p. e0123830  

See also: similar author names
1 Manzano, J.L.
4 Manzano, José Luis
4 Manzano, José Luís
2 Manzano, Julio
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.